$SGMO
Sangamo Therapeutics Inc

2018 Q1 Form 10-Q Financial Statement

#000156459018012641 Filed on May 10, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue $12.64M $13.08M $3.425M
YoY Change 268.96% 46.57% -13.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.09M $7.470M $7.280M
YoY Change 38.6% 53.7% 35.82%
% of Gross Profit
Research & Development $23.55M $19.38M $12.94M
YoY Change 81.94% 39.52% -15.22%
% of Gross Profit
Depreciation & Amortization $588.0K $500.0K $301.0K
YoY Change 95.35% 66.67% 22.86%
% of Gross Profit
Operating Expenses $33.63M $26.84M $20.22M
YoY Change 66.36% 43.15% -1.97%
Operating Profit -$21.00M -$16.79M
YoY Change 25.04% 0.67%
Interest Expense $810.0K $680.0K $160.0K
YoY Change 406.25% 209.09% -15.79%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$20.19M -$13.09M -$16.63M
YoY Change 21.41% 36.21% 0.82%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.19M -$13.09M -$16.63M
YoY Change 21.37% 36.02% 0.84%
Net Earnings / Revenue -159.75% -100.11% -485.61%
Basic Earnings Per Share
Diluted Earnings Per Share -$233.9K -$154.2K -$234.1K
COMMON SHARES
Basic Shares Outstanding 70.88M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $229.5M $243.3M $129.3M
YoY Change 77.49% 70.7% -31.44%
Cash & Equivalents $34.21M $49.83M $18.49M
Short-Term Investments $198.8M $193.5M $110.8M
Other Short-Term Assets $2.800M $1.500M $1.700M
YoY Change 64.71% -16.67% 183.33%
Inventory
Prepaid Expenses
Receivables $3.600M $3.343M $2.400M
Other Receivables $300.0K $300.0K $400.0K
Total Short-Term Assets $236.3M $248.4M $133.8M
YoY Change 76.61% 66.04% -29.98%
LONG-TERM ASSETS
Property, Plant & Equipment $33.60M $31.07M $7.300M
YoY Change 360.27% 370.7% 128.13%
Goodwill $1.585M
YoY Change 0.0%
Intangibles $0.00
YoY Change
Long-Term Investments $5.000M $1.000M $3.000M
YoY Change 66.67% 200.0%
Other Assets $4.700M $1.181M $1.200M
YoY Change 291.67% 598.82% 1100.0%
Total Long-Term Assets $44.90M $38.34M $13.00M
YoY Change 245.38% 362.44% 120.34%
TOTAL ASSETS
Total Short-Term Assets $236.3M $248.4M $133.8M
Total Long-Term Assets $44.90M $38.34M $13.00M
Total Assets $281.2M $286.7M $146.8M
YoY Change 91.55% 81.61% -25.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.00M $16.00K $7.400M
YoY Change 48.65% -99.38% 138.71%
Accrued Expenses $3.200M $5.500M $2.000M
YoY Change 60.0% 89.66% 17.65%
Deferred Revenue $28.35M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $49.40M $44.86M $13.10M
YoY Change 277.1% 237.51% 29.7%
LONG-TERM LIABILITIES
Long-Term Debt $25.40M $24.70M $3.900M
YoY Change 551.28% 533.33% 1850.0%
Other Long-Term Liabilities $24.00M $29.20M $4.100M
YoY Change 485.37% 548.89% -43.84%
Total Long-Term Liabilities $49.40M $53.90M $8.000M
YoY Change 517.5% 541.67% 6.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.40M $44.86M $13.10M
Total Long-Term Liabilities $49.40M $53.90M $8.000M
Total Liabilities $98.80M $98.84M $21.10M
YoY Change 368.26% 355.57% 19.89%
SHAREHOLDERS EQUITY
Retained Earnings -$514.5M -$495.5M
YoY Change 12.38%
Common Stock $697.3M $683.7M
YoY Change 18.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $182.4M $187.9M $125.7M
YoY Change
Total Liabilities & Shareholders Equity $281.2M $286.7M $146.8M
YoY Change 91.53% 81.61% -25.48%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$20.19M -$13.09M -$16.63M
YoY Change 21.37% 36.02% 0.84%
Depreciation, Depletion And Amortization $588.0K $500.0K $301.0K
YoY Change 95.35% 66.67% 22.86%
Cash From Operating Activities -$18.13M -$16.80M -$13.10M
YoY Change 38.43% 42.37% -35.78%
INVESTING ACTIVITIES
Capital Expenditures $2.616M -$900.0K $468.0K
YoY Change 458.97% 350.0% 85.71%
Acquisitions
YoY Change
Other Investing Activities -$9.000M $28.80M $6.500M
YoY Change -238.46% 343.08% -140.63%
Cash From Investing Activities -$11.57M $28.00M $6.100M
YoY Change -289.62% 351.61% -137.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.60M $23.00K
YoY Change 45973.91% -87.7%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.58M 12.30M 3.400M
YoY Change 211.26% -2560.0% 1600.0%
NET CHANGE
Cash From Operating Activities -18.13M -16.80M -13.10M
Cash From Investing Activities -11.57M 28.00M 6.100M
Cash From Financing Activities 10.58M 12.30M 3.400M
Net Change In Cash -19.12M 23.50M -3.600M
YoY Change 431.06% -485.25% -90.14%
FREE CASH FLOW
Cash From Operating Activities -$18.13M -$16.80M -$13.10M
Capital Expenditures $2.616M -$900.0K $468.0K
Free Cash Flow -$20.75M -$15.90M -$13.57M
YoY Change 52.93% 37.07% -34.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 sgmo Build To Suit Lease Obligations
BuildToSuitLeaseObligations
25449000
CY2018Q1 us-gaap Liabilities
Liabilities
98803000
CY2018Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
870000
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
696429000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-514549000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2802000
CY2017Q4 sgmo Build To Suit Lease Obligations
BuildToSuitLeaseObligations
24738000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1506000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-286000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-495479000
CY2017Q4 us-gaap Liabilities
Liabilities
98841000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
856000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
682809000
CY2018Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-385000
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
281168000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23547000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-20997000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10087000
CY2018Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
810000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
182365000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
33634000
CY2017Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
11035000
CY2017Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5479000
CY2018Q1 sgmo Collaboration Agreements
CollaborationAgreements
12551000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
28345000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
44859000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
29244000
CY2017Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
1012000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87041208
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87041208
CY2018Q1 sgmo Restricted Cash And Other Non Current Assets
RestrictedCashAndOtherNonCurrentAssets
4720000
CY2017Q4 sgmo Restricted Cash And Other Non Current Assets
RestrictedCashAndOtherNonCurrentAssets
4681000
CY2017Q4 us-gaap Assets
Assets
286741000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12942000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7275000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
20217000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16792000
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
160000
CY2018Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-217000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-72000
CY2018Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
133000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1334000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-77000
CY2018Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2268000
CY2018Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2701000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-18134000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
63401000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
54450000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2616000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-11567000
CY2017Q1 sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
3425000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-19118000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3575000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53326000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22061000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34208000
CY2017Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18486000
CY2017Q1 sgmo License Included In Accrued Liabilities
LicenseIncludedInAccruedLiabilities
950000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p></div>
CY2018Q1 sgmo Cash Equivalent Maturity Period Highly Liquid Investment
CashEquivalentMaturityPeriodHighlyLiquidInvestment
three months or less
CY2018Q1 sgmo Assets Amortized Cost
AssetsAmortizedCost
224300000
CY2017Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
223634000
CY2018Q1 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
8000
CY2018Q1 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
362000
CY2017Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
255000
CY2018Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
223946000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
223379000
CY2018Q1 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0
CY2018Q1 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2017Q1 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2018Q1 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P1Y
CY2018Q1 sgmo Cash Equivalents And Available For Sale Securities Mature Within Twenty Four Months
CashEquivalentsAndAvailableForSaleSecuritiesMatureWithinTwentyFourMonths
5000000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2007 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q1 sgmo Percentage Of Disallowance Of Entertainment Expense
PercentageOfDisallowanceOfEntertainmentExpense
1.00
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3050000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2788000

Files In Submission

Name View Source Status
0001564590-18-012641-index-headers.html Edgar Link pending
0001564590-18-012641-index.html Edgar Link pending
0001564590-18-012641.txt Edgar Link pending
0001564590-18-012641-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201805100134042773894.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20180331.htm Edgar Link pending
sgmo-20180331.xml Edgar Link completed
sgmo-20180331.xsd Edgar Link pending
sgmo-20180331_cal.xml Edgar Link unprocessable
sgmo-20180331_def.xml Edgar Link unprocessable
sgmo-20180331_lab.xml Edgar Link unprocessable
sgmo-20180331_pre.xml Edgar Link unprocessable
sgmo-ex101_180.htm Edgar Link pending
sgmo-ex102_123.htm Edgar Link pending
sgmo-ex311_8.htm Edgar Link pending
sgmo-ex312_6.htm Edgar Link pending
sgmo-ex321_7.htm Edgar Link pending
Show.js Edgar Link pending